Literature DB >> 15824409

The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.

Douglas G Manuel1, Peter Tanuseputro, Cameron A Mustard, Susan E Schultz, Geoffrey M Anderson, Sten Ardal, David A Alter, Andreas Laupacis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15824409      PMCID： PMC556042          DOI： 10.1503/cmaj.1040202

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  17 in total

1.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors:  J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment?

Authors:  Frans H Rutten; Eelko Hak; Wim A B Stalman; Theo J M Verheij; Arno W Hoes
Journal:  Fam Pract       Date:  2003-02       Impact factor: 2.267

3.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

Authors:  J C LaRosa; J He; S Vupputuri
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

4.  When should hypertension be treated? The different perspectives of Canadian family physicians and patients.

Authors:  F A McAlister; A M O'Connor; G Wells; S A Grover; A Laupacis
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

5.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.

Authors:  Dennis T Ko; Muhammad Mamdani; David A Alter
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

6.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

7.  Adherence with statin therapy in elderly patients with and without acute coronary syndromes.

Authors:  Cynthia A Jackevicius; Muhammad Mamdani; Jack V Tu
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

8.  Long-term persistence in use of statin therapy in elderly patients.

Authors:  Joshua S Benner; Robert J Glynn; Helen Mogun; Peter J Neumann; Milton C Weinstein; Jerry Avorn
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

9.  Cardiovascular disease risk profiles.

Authors:  K M Anderson; P M Odell; P W Wilson; W B Kannel
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
View more
  11 in total

1.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

2.  Questioning the benefits of statins.

Authors:  Eddie Vos; Colin P Rose
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

3.  Questioning the benefits of statins.

Authors:  Garey Mazowita
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

4.  The analysis by Manuel and colleagues creates controversy with headlines, not data.

Authors:  Jacques Genest; Ruth McPherson; Jiri Frohlich; George Fodor
Journal:  CMAJ       Date:  2005-04-12       Impact factor: 8.262

5.  The Canadian lipid guidelines are difficult to model quantitatively.

Authors:  Daniel T Holmes; Jiri J Frohlich
Journal:  Can J Cardiol       Date:  2008-08       Impact factor: 5.223

6.  Statins and primary prevention: is all the evidence in?

Authors:  Shirya Rashid; Gordon A Francis
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

Review 7.  Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues.

Authors:  Yola Moride; Robert A Hegele; Anatoly Langer; Ruth McPherson; David B Miller; Stéphane Rinfret
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

8.  Statin use in Canadians: trends, determinants and persistence.

Authors:  C Ineke Neutel; Howard Morrison; Norm R C Campbell; Margaret de Groh
Journal:  Can J Public Health       Date:  2007 Sep-Oct

9.  The relationship between physician supply, cardiovascular health service use and cardiac disease burden in Ontario: supply-need mismatch.

Authors:  David A Alter; Therese A Stukel; Alice Newman
Journal:  Can J Cardiol       Date:  2008-03       Impact factor: 5.223

10.  Does screening for peripheral arterial disease improve risk stratification for patients at intermediate risk for coronary artery disease?

Authors:  Michelle Greiver
Journal:  Open Med       Date:  2007-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.